7,8-Dihydroxyflavone attenuates the release of pro-inflammatory mediators and cytokines in lipopolysaccharide-stimulated BV2 microglial cells through the suppression of the NF-κB and MAPK signaling pathways

Park,Hye Young; Park,Cheol; Hwang,Hye Jin; Kim,Byung Woo; Kim,Gi-Young; Kim,Cheol Min; Kim,Nam Deuk; Choi,Yung Hyun

doi:10.3892/ijmm.2014.1652

7,8-Dihydroxyflavone attenuates the release of pro-inflammatory mediators and cytokines in lipopolysaccharide-stimulated BV2 microglial cells through the suppression of the NF-κB and MAPK signaling pathways

Authors:
- Hye Young Park
- Cheol Park
- Hye Jin Hwang
- Byung Woo Kim
- Gi-Young Kim
- Cheol Min Kim
- Nam Deuk Kim
- Yung Hyun Choi
View Affiliations

Affiliations: Department of Pharmacy, Busan National University, Busan 609-735, Republic of Korea, Department of Molecular Biology, Dongeui University, Busan 614-714, Republic of Korea, Department of Food and Nutrition, Dongeui University, Busan 614-714, Republic of Korea, Department of Life Science and Biotechnology, Dongeui University, Busan 614-714, Republic of Korea, Laboratory of Immunobiology, Department of Marine Life Sciences, Jeju National University, Jeju 690-756, Republic of Korea, Research Center for Anti-Aging Technology Development and Department of Biochemistry, Busan National University College of Medicine, Yangsan 626-870, Republic of Korea, Department of Anti-Aging Research Center and Blue-Bio Industry RIC, Dongeui University, Busan 614-714, Republic of Korea
Published online on: February 10, 2014 https://doi.org/10.3892/ijmm.2014.1652
Pages: 1027-1034

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

7,8-Dihydroxyflavone (7,8-DHF), a member of the flavonoid family, has received considerable attention as a selective tyrosine kinase receptor B agonist. However, the pharmacological mechanisms responsible for its anti-inflammatory activities in microglial cells have yet to be elucidated. In this study, we evaluated the anti-inflammatory effects of this compound on the production of inflammatory mediators and cytokines in lipopolysaccharide (LPS)-stimulated murine BV2 microglial cells. At non-toxic concentrations, 7,8-DHF attenuated the production of nitric oxide (NO) and prostaglandin E2 (PGE2), by inhibiting inducible NO synthase (iNOS) and cyclooxygenase-2 (COX-2) expression, respectively. Furthermore, the release and expression of inflammatory cytokines, including tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β), were inhibited by 7,8-DHF. In addition, 7,8-DHF suppressed nuclear factor‑κB (NF-κB) translocation and its transcriptional activity by blocking IκB (IκB)-α degradation; in addition, it exerted suppressive effects on the phosphorylation of mitogen-activated protein kinases (MAPKs). These results indicate that 7,8-DHF possesses therapeutic potential against neurodegenerative diseases that involve microglial activation.

View Figures

View References

1	Napoli I and Neumann H: Microglial clearance function in health and disease. Neuroscience. 158:1030–1038. 2009. View Article : Google Scholar : PubMed/NCBI
2	Loane DJ and Byrnes KR: Role of microglia in neurotrauma. Neurotherapeutics. 7:366–377. 2010. View Article : Google Scholar : PubMed/NCBI
3	Meda L, Cassatella MA, Szendrei GI, Otvos L Jr, Baron P, Villalba M, Ferrari D and Rossi F: Activation of microglial cells by β-amyloid protein and interferon-γ. Nature. 373:647–650. 1995.
4	Eikelenboom P and van Gool WA: Neuroinflammatory perspectives on the two faces of Alzheimer’s disease. J Neural Transm. 111:281–294. 2004.PubMed/NCBI
5	Gao HM, Liu B, Zhang W and Hong JS: Novel anti-inflammatory therapy for Parkinson’s disease. Trends Pharmacol Sci. 24:395–401. 2003.
6	Liu B and Hong JS: Role of microglia in inflammation-mediated neurodegenerative diseases: mechanisms and strategies for therapeutic intervention. J Pharmacol Exp Ther. 304:1–7. 2003. View Article : Google Scholar : PubMed/NCBI
7	Rock RB and Peterson PK: Microglia as a pharmacological target in infectious and inflammatory diseases of the brain. J Neuroimmune Pharmacol. 1:117–126. 2006. View Article : Google Scholar : PubMed/NCBI
8	Kaur C and Ling EA: Antioxidants and neuroprotection in the adult and developing central nervous system. Curr Med Chem. 15:3068–3080. 2008. View Article : Google Scholar : PubMed/NCBI
9	Deng YY, Lu J, Ling EA and Kaur C: Role of microglia in the process of inflammation in the hypoxic developing brain. Front Biosci (Schol Ed). 3:884–900. 2011. View Article : Google Scholar : PubMed/NCBI
10	Ramos S: Cancer chemoprevention and chemotherapy: dietary polyphenols and signalling pathways. Mol Nutr Food Res. 52:507–526. 2008. View Article : Google Scholar : PubMed/NCBI
11	Guo W, Kong E and Meydani M: Dietary polyphenols, inflammation, and cancer. Nut Cancer. 61:807–810. 2009. View Article : Google Scholar : PubMed/NCBI
12	Chen S: Natural products triggering biological targets-a review of the anti-inflammatory phytochemicals targeting the arachidonic acid pathway in allergy asthma and rheumatoid arthritis. Curr Drug Targets. 12:288–301. 2011. View Article : Google Scholar
13	García-Lafuente A, Guillamón E, Villares A, Rostagno MA and Martínez JA: Flavonoids as anti-inflammatory agents: implications in cancer and cardiovascular disease. Inflamm Res. 58:537–552. 2009.PubMed/NCBI
14	González-Gallego J, García-Mediavilla MV, Sánchez-Campos S and Tuñón MJ: Fruit polyphenols, immunity and inflammation. Br J Nut. 104(Suppl 3): S15–S27. 2010.PubMed/NCBI
15	Magrone T and Jirillo E: Potential application of dietary polyphenols from red wine to attaining healthy ageing. Curr Top Med Chem. 11:1780–1796. 2011. View Article : Google Scholar : PubMed/NCBI
16	Juurlink BH and Paterson PG: Review of oxidative stress in brain and spinal cord injury: suggestions for pharmacological and nutritional management strategies. J Spinal Cord Med. 21:309–334. 1998.PubMed/NCBI
17	Ramassamy C: Emerging role of polyphenolic compounds in the treatment of neurodegenerative diseases: a review of their intracellular targets. Eur J Pharmacol. 545:51–64. 2006. View Article : Google Scholar : PubMed/NCBI
18	del Campos-Esparza MR and Torres-Ramos MA: Neuroprotection by natural polyphenols: molecular mechanisms. Cent Nerv Syst Agents Med Chem. 10:269–277. 2010.PubMed/NCBI
19	Jang SW, Liu X, Yepes M, Shepherd KR, Miller GW, Liu Y, Wilson WD, Xiao G, Blanchi B, Sun YE and Ye K: A selective TrkB agonist with potent neurotrophic activities by 7,8-dihydroxyflavone. Proc Natl Acad Sci USA. 107:2687–2692. 2010. View Article : Google Scholar : PubMed/NCBI
20	Andero R, Heldt SA, Ye K, Liu X, Armario A and Ressler KJ: Effect of 7,8-dihydroxyflavone, a small-molecule TrkB agonist, on emotional learning. Am J Psychiatry. 168:163–172. 2011. View Article : Google Scholar : PubMed/NCBI
21	Chen J, Chua KW, Chua CC, Yu H, Pei A, Chua BH, Hamdy RC, Xu X and Liu CF: Antioxidant activity of 7,8-dihydroxyflavone provides neuroprotection against glutamate-induced toxicity. Neurosci Lett. 499:181–185. 2011. View Article : Google Scholar : PubMed/NCBI
22	Zhang R, Kang KA, Piao MJ, Ko DO, Wang ZH, Chang WY, You HJ, Lee IK, Kim BJ, Kang SS and Hyun JW: Preventive effect of 7,8-dihydroxyflavone against oxidative stress induced genotoxicity. Biol Pharm Bull. 32:166–171. 2009. View Article : Google Scholar : PubMed/NCBI
23	Kozics K, Valovicova Z and Slamenova D: Structure of flavonoids influences the degree inhibition of Benzo(a)pyrene-induced DNA damage and micronuclei in HepG2 cells. Neoplasma. 58:516–524. 2011. View Article : Google Scholar : PubMed/NCBI
24	Park HY, Kim GY, Hyun JW, Hwang HJ, Kim ND, Kim BW and Choi YH: 7,8-Dihydroxyflavone exhibits anti-inflammatory properties by downregulating the NF-κB and MAPK signaling pathways in lipopolysaccharide-treated RAW264.7 cells. Int J Mol Med. 29:1146–1152. 2012.PubMed/NCBI
25	Kyung J, Kim D, Park D, Yang YH, Choi EK, Lee SP, Kim TS, Lee YB and Kim YB: Synergistic anti-inflammatory effects of Laminaria japonica fucoidan and Cistanche tubulosa extract. Lab Anim Res. 28:91–97. 2012. View Article : Google Scholar
26	Lee SH, Kim DW, Eom SA, Jun SY, Park M, Kim DS, Kwon HJ, Kwon HY, Han KH, Park J, Hwang HS, Eum WS and Choi SY: Suppression of 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced skin inflammation in mice by transduced Tat-Annexin protein. BMB Rep. 45:354–359. 2012. View Article : Google Scholar : PubMed/NCBI
27	McGeer PL, Yasojima K and McGeer EG: Inflammation in Parkinson’s disease. Adv Neurol. 86:83–89. 2001.
28	Leone S, Ottani A and Bertolini A: Dual acting anti-inflammatory drugs. Curr Topics Med Chem. 7:265–275. 2007. View Article : Google Scholar
29	Mariani MM and Kielian T: Microglia in infectious diseases of the central nervous system. J Neuroimmune Pharmacol. 4:448–461. 2009. View Article : Google Scholar : PubMed/NCBI
30	Saha RN and Pahan K: Regulation of inducible nitric oxide synthase gene in glial cells. Antioxid Redox Signal. 8:929–947. 2006. View Article : Google Scholar : PubMed/NCBI
31	Brown GC and Neher JJ: Inflammatory neurodegeneration and mechanisms of microglial killing of neurons. Mol Neurobiol. 41:242–247. 2010. View Article : Google Scholar : PubMed/NCBI
32	Hawkey CJ: COX-2 inhibitors. Lancet. 353:307–314. 1999. View Article : Google Scholar
33	Vane JR, Mitchell JA, Appleton I, Tomlinson A, Bishop-Bailey D, Croxtall J and Willoughby DA: Inducible isoforms of cyclooxygenase and nitric-oxide synthase in inflammation. Proc Natl Acad Sci USA. 91:2046–2050. 1994. View Article : Google Scholar : PubMed/NCBI
34	Giovannini MG, Scali C, Prosperi C, Bellucci A, Pepeu G and Casamenti G: Experimental brain inflammation and neurodegeneration as model of Alzheimer’s disease: protective effects of selective COX-2 inhibitors. Int J Immunopathol Pharmacol. 16(Suppl 2): S31–S40. 2003.
35	Minghetti L and Pocchiari M: Cyclooxygenase-2, prostaglandin E₂, and microglial activation in prion diseases. Int Rev Neurobiol. 82:265–275. 2007. View Article : Google Scholar
36	Choi SH, Aid S and Bosetti F: The distinct roles of cyclooxygenase-1 and −2 in neuroinflammation: implications for translational research. Trends Pharmacol Sci. 30:174–181. 2009.
37	Boka G, Anglade P, Wallach D, Javoy-Agid F, Agid Y and Hirsch EC: Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson’s disease. Neurosc Lett. 172:151–154. 1994.PubMed/NCBI
38	Hunot S, Dugas N, Faucheux B, Hartmann A, Tardieu M, Debre P, Agid Y, Dugas B and Hirsch EC: FcepsilonRII/CD23 is expressed in Parkinson’s disease and induces, in vitro, production of nitric oxide and tumor necrosis factor-alpha in glial cells. J Neurosci. 19:3440–3447. 1999.PubMed/NCBI
39	De Nardin E: The role of inflammatory and immunological mediators in periodontitis and cardiovascular disease. Ann Periodontol. 6:30–40. 2001.PubMed/NCBI
40	Sawada M, Kondo N, Suzumura A and Marunouchi T: Production of tumor necrosis factor-alpha by microglia and astrocytes in culture. Brain Res. 491:394–397. 1989. View Article : Google Scholar : PubMed/NCBI
41	Botchkina GI, Meistrell ME III, Botchkina IL and Tracey KJ: Expression of TNF and TNF receptors (p55 and p75) in the rat brain after focal cerebral ischemia. Mol Med. 3:765–781. 1997.PubMed/NCBI
42	Akassoglou K, Bauer J, Kassiotis G, Pasparakis M, Lassmann H, Kollias G and Probert L: Oligodendrocyte apoptosis and primary demyelination induced by local TNF/p55TNF receptor signaling in the central nervous system of transgenic mice: models for multiple sclerosis with primary oligodendrogliopathy. Am J Pathol. 153:801–813. 1998. View Article : Google Scholar
43	Sriram K, Matheson JM, Benkovic SA, Miller DB, Luster MI and O’Callaghan JP: Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: implications for Parkinson’s disease. FASEB J. 16:1474–1476. 2002.PubMed/NCBI
44	Gougeon PY, Lourenssen S, Han TY, Nair DG, Ropeleski MJ and Blennerhassett MG: The pro-inflammatory cytokines IL-1β and TNFα are neurotrophic for enteric neurons. J Neurosci. 33:3339–3351. 2013.
45	Rothwell N, Allan S and Toulmond S: The role of interleukin 1 in acute neurodegeneration and stroke: pathophysiological and therapeutic implications. J Clin Invest. 100:2648–2652. 1997. View Article : Google Scholar : PubMed/NCBI
46	Haddad JJ: The role of inflammatory cytokines and NF-kappaB/MAPK signaling pathways in the evolution of familial Mediterranean fever: current clinical perspectives and potential therapeutic approaches. Cell Immunol. 260:6–13. 2009. View Article : Google Scholar
47	Hamilton T, Novotny M, Pavicic PJ Jr, Herjan T, Hartupee J, Sun D, Zhao C and Datta S: Diversity in post-transcriptional control of neutrophil chemoattractant cytokine gene expression. Cytokine. 52:116–122. 2010. View Article : Google Scholar : PubMed/NCBI
48	Baldwin AS Jr: The NF-kappa B and I kappa B proteins: new discoveries and insights. Ann Rev Immunol. 14:649–683. 1996. View Article : Google Scholar : PubMed/NCBI
49	Moon DO, Choi YH, Kim ND, Park YM and Kim GY: Anti-inflammatory effects of beta-lapachone in lipopolysaccharide-stimulated BV2 microglia. Int Immunopharmacol. 7:506–514. 2007. View Article : Google Scholar : PubMed/NCBI
50	Sarkar FH and Li Y: NF-kappaB: a potential target for cancer chemoprevention and therapy. Front Biosci. 13:2950–2959. 2008. View Article : Google Scholar : PubMed/NCBI
51	Wertz IE and Dixit VM: Signaling to NF-kappaB: regulation by ubiquitination. Cold Spring Harb Perspect Biol. 2:a0033502010. View Article : Google Scholar : PubMed/NCBI
52	Mattson MP and Camandola S: NF-kappaB in neuronal plasticity and neurodegenerative disorders. J Clin Invest. 107:247–254. 2001. View Article : Google Scholar : PubMed/NCBI
53	Nakajima K and Kohsaka S: Characterization of brain microglia and the biological significance in the central nervous system. Adv Neurol. 60:734–743. 1993.PubMed/NCBI
54	Kim YJ, Hwang SY, Oh ES, Oh S and Han IO: IL-1beta, an immediate early protein secreted by activated microglia, induces iNOS/NO in C6 astrocytoma cells through p38 MAPK and NF-kappaB pathways. J Neurosci Res. 84:1037–1046. 2006. View Article : Google Scholar : PubMed/NCBI